Mutual of America Capital Management LLC Has $1.30 Million Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Mutual of America Capital Management LLC reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 5.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 67,187 shares of the biotechnology company’s stock after selling 3,924 shares during the quarter. Mutual of America Capital Management LLC owned approximately 0.05% of Arrowhead Pharmaceuticals worth $1,301,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 16.2% during the 1st quarter. Vanguard Group Inc. now owns 12,404,050 shares of the biotechnology company’s stock valued at $354,756,000 after buying an additional 1,731,974 shares during the period. Avoro Capital Advisors LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 3.9% during the second quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock worth $231,022,000 after acquiring an additional 333,333 shares in the last quarter. Millennium Management LLC boosted its position in Arrowhead Pharmaceuticals by 61.9% during the second quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock valued at $13,755,000 after purchasing an additional 202,280 shares during the last quarter. International Assets Investment Management LLC purchased a new position in Arrowhead Pharmaceuticals in the third quarter valued at about $14,420,000. Finally, Bank of Montreal Can increased its position in Arrowhead Pharmaceuticals by 240.5% in the 2nd quarter. Bank of Montreal Can now owns 43,699 shares of the biotechnology company’s stock worth $1,202,000 after purchasing an additional 30,866 shares during the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ARWR. B. Riley reiterated a “buy” rating and set a $55.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. Piper Sandler restated an “overweight” rating and set a $62.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, October 8th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Tuesday, November 12th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.33.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR opened at $18.79 on Tuesday. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $17.05 and a 52-week high of $39.83. The company has a market cap of $2.34 billion, a P/E ratio of -4.02 and a beta of 0.93. The stock’s 50-day moving average is $19.82 and its 200-day moving average is $23.17.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.